Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT (REKLAIM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05739643 |
|
Recruitment Status :
Recruiting
First Posted : February 22, 2023
Last Update Posted : April 26, 2024
|
Sponsor:
Forge Biologics, Inc
Information provided by (Responsible Party):
Forge Biologics, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product after HSCT. Data from previously transplanted patients with infantile and late infantile Krabbe disease will be used as a comparator group.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Krabbe Disease | Biological: FBX-101 | Phase 1 Phase 2 |
The FBX-101-REKLAIM study has been modified on Q4 2023 to allow a broader patient recruitment of infantile and late infantile Krabbe patients. The updated REKLAIM study merges the recruitment populations of the previous FBX-101-RESKUE clinical trial (NCT04693598) and the FBX-101-REKLAIM clinical trial (NCT05739643).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 9 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Dose escalation study from a low dose to a high dose following safety review |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b Clinical Study of Intravenous AAVrh10 Vector Expressing GALC in Krabbe Subjects Who Previously Received Hematopoietic Stem Cell Transplantation (REKLAIM) |
| Actual Study Start Date : | February 3, 2023 |
| Estimated Primary Completion Date : | July 2026 |
| Estimated Study Completion Date : | July 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Krabbe disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1 - Low Dose FBX-101 (aka AAVrh.10-GALC)
N=3 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the low dose
|
Biological: FBX-101
A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Other Name: AAVrh.10-hGALC |
|
Experimental: Cohort 2 - High Dose FBX-101 (aka AAVrh.10-GALC)
N=3-6 patients with Infantile or Late Infantile Krabbe disease will receive a single infusion at the high dose
|
Biological: FBX-101
A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Other Name: AAVrh.10-hGALC |
Primary Outcome Measures :
- Safety as assessed by incidence and severity of adverse events and serious adverse events that are attributed to FBX-101 [ Time Frame: 24 months ]
Secondary Outcome Measures :
- Efficacy as assessed by improvement of gross motor function as measured longitudinally by PDMS-2, BOTMP2, or by GMFM-88, depending on the age, compared to patients receiving HSCT only [ Time Frame: 12 months and 24 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Group Infantile Krabbe: Subjects who are going to be transplanted or have already been transplanted for asymptomatic infantile onset Krabbe disease with initial diagnosis based on:
- Galactocerebrosidase (GALC) activity levels in leukocytes compatible with the diagnosis of infantile Krabbe disease; AND AT LEAST ONE OF THE FOLLOWING:
- Psychosine levels predictive of infantile onset by Dried Blood Spot (DBS); OR
- Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR); OR
- Two GALC mutations predictive to result in infantile onset phenotype.
-
Group Late Infantile Krabbe: Subjects who are going to be transplanted or have already been transplanted for symptomatic late infantile onset Krabbe with initial diagnosis based on:
- Galactocerebrosidase (GALC) activity levels in leukocytes compatible with the diagnosis of late infantile Krabbe disease; AND AT LEAST ONE OF THE FOLLOWING:
- Psychosine levels predictive of late infantile onset by DBS; OR
- Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR); OR
- Two GALC mutations predictive to result in late infantile onset phenotype; OR
- Neurological/developmental exam findings consistent with late infantile Krabbe disease
- Participants must be considered candidates for HSCT or have received HSCT at least 21 days prior to dosing date
- For patients already transplanted and followed for more than 3 months chimerism should reflect at least 30% of myeloid cells from the donor by month 3 post-transplant, from 30 to 10% between 3 months and one year post-transplant or 10% by one year post-transplant.
-
Participant must have adequate organ function at time of screening or evaluation as measured by:
- Ejection fraction of > 50% by echocardiogram or other appropriate study without evidence of pulmonary hypertension.
- Pulmonary evaluation testing demonstrating resting pulse oximeter > 95% on room air.
- Absence of active aspiration
- Participant's parents or legal guardian consent to participate in the study and provide informed consent according to IRB/IEC guidelines prior to any study procedures being performed
- Parent(s) and/or legal guardian able to comply with the clinical protocol
Exclusion Criteria:
- Immunoassay with total anti-AAVrh10 antibody titers of >1:100. This criteria will not apply to children screened before they have received HSCT or for children who sign the inform consent within 60 days from HSCT.
- History of prior treatment with a gene therapy product
- Inability to actively move upper extremities against gravity
- Grade 2 or higher abnormalities in LFTs, bilirubin, creatinine, white count, hemoglobin, platelets, PT/INR and PTT according to latest version of CTCAE
- Presence of any neurocognitive deficit, motor deficit, or brain damage not attributable to Krabbe disease
- Signs of active infections or disease from cytomegalovirus, adenovirus, EBV, hepatitis B or C, and HIV or other viruses excluding rhinovirus from RVP and asymptomatic norovirus presence in stool. Patients showing HIV positive results will be excluded from the study.
- Active bacterial or fungal infection documented the preceding 7 days.
- Presence of any contraindication for MRI or lumbar puncture (LP)
- Use of any investigational product prior to study enrollment or current enrollment in another study that involves clinical interventions
- Immunizations with live viruses in the 30 days prior to immune suppression
- Active acute Graft Versus Host Disease (GvHD) Grade II or higher according to modified Glucksberg criteria (Przepiorka et al., 1995) or active, moderate or severe, chronic GvHD according to revised NIH criteria (Jagasia et al., 2015)
- Any other medical condition, serious intercurrent illness, other genetic condition or extenuating circumstance that, in the opinion of the PI, would preclude participation in the study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05739643
Contacts
| Contact: Kelly Bossola | +1.380.239.2052 | advocacy@forgebiologics.com | |
| Contact: Maria Escolar | +1.412-499-4658 | advocacy@forgebiologics.com |
Locations
| United States, California | |
| Children's Hospital of Orange County (CHOC) | Recruiting |
| Orange, California, United States, 92868 | |
| Contact: Nina Movsesyan, PhD 714-509-3008 nmovsesyan@choc.org | |
| Contact: Raymond Wang, MD rawang@choc.org | |
| Principal Investigator: Raymond Wang, MD | |
| United States, Michigan | |
| University of Michigan Hospitals - Michigan Medicine | Recruiting |
| Ann Arbor, Michigan, United States, 48109 | |
| Contact: Mark Vander Lugt, MD 616-340-7643 marvande@med.umich.edu | |
| Contact: Bre'Anna Simpson 734-615-4630 sbreanna@med.umich.edu | |
| Principal Investigator: Mark Vander Lugt, MD | |
Sponsors and Collaborators
Forge Biologics, Inc
Publications:
| Responsible Party: | Forge Biologics, Inc |
| ClinicalTrials.gov Identifier: | NCT05739643 |
| Other Study ID Numbers: |
FBX-101-REKLAIM |
| First Posted: | February 22, 2023 Key Record Dates |
| Last Update Posted: | April 26, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Forge Biologics, Inc:
|
Leukodystrophy, Globoid Cell Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Sphingolipidoses Lysosomal Storage Diseases, Nervous System |
Leukoencephalopathies Demyelinating Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |
Additional relevant MeSH terms:
|
Leukodystrophy, Globoid Cell Hereditary Central Nervous System Demyelinating Diseases Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Sphingolipidoses Lysosomal Storage Diseases, Nervous System |
Leukoencephalopathies Demyelinating Diseases Metabolism, Inborn Errors Genetic Diseases, Inborn Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |